OLD National Bancorp IN Has $10.71 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

OLD National Bancorp IN increased its stake in Bristol-Myers Squibb (NYSE:BMY) by 0.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 206,914 shares of the biopharmaceutical company’s stock after purchasing an additional 1,113 shares during the period. OLD National Bancorp IN’s holdings in Bristol-Myers Squibb were worth $10,706,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Cyndeo Wealth Partners LLC boosted its stake in Bristol-Myers Squibb by 3.9% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 9,535 shares of the biopharmaceutical company’s stock worth $493,000 after purchasing an additional 357 shares during the period. Wealth Alliance Advisory Group LLC boosted its stake in Bristol-Myers Squibb by 159.1% in the 3rd quarter. Wealth Alliance Advisory Group LLC now owns 17,640 shares of the biopharmaceutical company’s stock worth $913,000 after purchasing an additional 10,831 shares during the period. Alta Wealth Advisors LLC boosted its stake in Bristol-Myers Squibb by 2.4% in the 3rd quarter. Alta Wealth Advisors LLC now owns 18,051 shares of the biopharmaceutical company’s stock worth $934,000 after purchasing an additional 419 shares during the period. ST Germain D J Co. Inc. boosted its stake in shares of Bristol-Myers Squibb by 4.7% during the 3rd quarter. ST Germain D J Co. Inc. now owns 22,746 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 1,021 shares during the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Bristol-Myers Squibb by 50.0% during the 3rd quarter. Blue Trust Inc. now owns 25,501 shares of the biopharmaceutical company’s stock worth $1,319,000 after buying an additional 8,498 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Sanford C. Bernstein assumed coverage on shares of Bristol-Myers Squibb in a research note on Thursday. They set a “market perform” rating and a $56.00 price objective for the company. TD Cowen increased their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. UBS Group increased their price objective on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 9th. Finally, Jefferies Financial Group raised their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research note on Wednesday, August 28th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $53.20.

Bristol-Myers Squibb Stock Up 0.1 %

Bristol-Myers Squibb stock opened at $53.22 on Friday. The stock has a market cap of $107.88 billion, a P/E ratio of -17.17, a P/E/G ratio of 13.75 and a beta of 0.46. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $57.09. The company’s 50-day moving average price is $50.36 and its two-hundred day moving average price is $46.37.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The company had revenue of $12.20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. During the same period last year, the firm earned $1.75 earnings per share. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. As a group, analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.51%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.